Presentation is loading. Please wait.

Presentation is loading. Please wait.

BRAF V600E Mutation Is not Always Present as Expected

Published byHarjanti Halim Modified over 5 years ago

Similar presentations

Presentation on theme: "BRAF V600E Mutation Is not Always Present as Expected"— Presentation transcript:

1 BRAF V600E Mutation Is not Always Present as Expected
BRAF V600E Mutation Is not Always Present as Expected! A Case Report of Lung and Thyroid Carcinomas  Nicolas Piton, MD, MPhil, Mathieu Salaün, MD, PhD, Florian Guisier, MD, MRes, Florent Marguet, MD, MRes, Emmanuel K. Touré, MD, Pierre Gémival, MD, Luc Thiberville, MD, PhD, Jean-Christophe Sabourin, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Computed tomography scans: mediastinal window (I), parenchymal window (II), initially (day 0) (A), and after treatment by carboplatin-taxol (day 170) (B). Mediastinal lymph nodes have increased in size (I), and an ill-defined lesion has appeared in the right lower lobe with right pleural effusion (II). (C) After second-line treatment with dabrafenib (day 483), mediastinal lymph nodes and the right lung lesion have dramatically regressed, with only a mild right pleural effusion remaining. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Photomicrographs of formalin-fixed paraffin-embedded tissue section of a cervical lymph node after staining by hematoxylin and eosin and by Safran (A) and immunostaining for BRAF V600E (B). This lymph node is infiltrated by both a papillary thyroid carcinoma for which the results of staining for BRAF V600E were negative (white star) and a BRAF V600E–positive adenocarcinoma (black star and arrow). Bar scales: 50 μm for (AI), (BI), (AIII), and (BIII) and 200 μm for (AII) and (BII). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "BRAF V600E Mutation Is not Always Present as Expected"

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Primary Mucoepidermoid Carcinoma of the Esophagus

Primary Mucoepidermoid Carcinoma of the Esophagus
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD 

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
The Case of the Missed Chest Radiograph: Bilateral Mammary Gland Metastases Mimicking Multifocal Primary Breast Cancer as the Initial Manifestation of.

The Case of the Missed Chest Radiograph: Bilateral Mammary Gland Metastases Mimicking Multifocal Primary Breast Cancer as the Initial Manifestation of.
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Sclerosing Pneumocytoma with Lymph Node Metastasis

Sclerosing Pneumocytoma with Lymph Node Metastasis
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

Similar presentations

Ads by Google